RPG Life Sciences Spins Off API Unit in Up to ₹700 Cr Deal

RPG Life Sciences is spinning off its Active Pharmaceutical Ingredient (API) business into a wholly-owned subsidiary, RPG Active Pharma, to create a focused and operationally flexible platform. To fuel this expansion, the company has partnered with private equity firm InvAscent, which will make an initial investment of up to Rs 243 crore as part of a broader plan involving up to Rs 700 crore in multi-tranche investments. Simultaneously, RPG Active Pharma has signed an agreement to acquire 100% of Actis Generics, a Visakhapatnam-based API manufacturer, to bolster its global market presence and production capacity.

News by Rahul Yelligetti.